AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|July 27, 2009
Make Your Laboratories More Efficient, and More Profitable
With thousands of UPLC systems and UPLC columns delivered worldwide, see why the world's top-branded companies and institutions have standardized on ACQUITY UPLC: the fastest-growing new LC platform in the market for five years running.
Advertisement
"We're always looking to improve quality and efficiency in our group, and UPLC® answered this for us. Waters has a reputation for being the gold standard of high-pressure chromatography." - Powell K., Enthalpy Analytical, Inc.
To satisfy their customers' fundamental need for faster, high-quality laboratory results, one analytical services organization selected the Waters ACQUITY UPLC® System - it also matched the company's overall streamlining efforts.
As many pharmaceutical companies strive to shorten drug development time by using contract laboratories, these organizations are increasingly relied upon for not only their analytical expertise, but also for offering far greater efficiencies at a lower cost. With a robust laboratory workflow, it's easy to stand out from competitors.
Eliminate analytical work backlogs and slow turnaround times
Increase laboratory flexibility, quality, and efficiency
Assure capacity ahead of increasing demand, and can commit to meet deadlines consistently
CONTACT:
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
Roundup: AbbVie & Lambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
5